Artificial Intelligence Guided Personalised Medicine in Patients With Hypertension and Diabetes
试验速览
- 阶段
- 不适用
- 入组人数
- 40
- 主要终点
- Medication dosing optimization
研究概览
简要总结
Hypertension and diabetes are chronic diseases that require long-term management and disease control is often sub-optimal, leading to complications which place additional burden on patients and the healthcare system.
This study aims to address factors such as gender, ethnicity and specific genetics that are not routinely considered during drug dosing but account for considerable variations in drug responses by tailoring the treatment to individual patient using CURATE.AI. CURATE.AI is an artificial intelligence guided dosing decision tool and can be applicable across many different conditions, as it is disease agnostic. This platform had demonstrated initial success in cancer and transplant populations but has yet to be applied to chronic disease patients.
The aim of this study is demonstrate that artificial intelligence guided treatment in chronic disease of hypertension and type 2 diabetes mellitus will yield actionable medication dosing optimization.
详细描述
The aim of this study is demonstrate that artificial intelligence guided treatment in chronic disease of hypertension and type 2 diabetes mellitus will yield actionable medication dosing optimization.
Study Objectives
- Artificial intelligence (CURATE.AI) pilot deployment using prospective data in patients with hypertension and type 2 diabetes mellitus.
- Artificial intelligence (CURATE.AI) for behavioural assessment and compliance prediction to disease management programme in patients with hypertension and type 2 diabetes mellitus.
Methods and Analysis Design and setting
This prospective cohort feasibility study will evaluate the blood pressure (n=20) and glycaemic (n=20) control of patients using the CURATE.AI platform. Participants will be recruited for a period of 4 months from the day of baseline visit and followed up for up to 4 clinic visits.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients (≥ 21years) with T2DM or hypertension
- •Expected to be followed up in Alexandra Hospital for the next 4-months
- •Signed informed consent form
排除标准
- •Patients with cognitive impairment
- •Patients with active cancer undergoing chemotherapy
- •Patients on hemodialysis or peritoneal dialysis (which can cause rapid fluctuation of BP and blood sugar, respectively)
- •Pregnant patients
- •Patients whose medications for T2DM and hypertension are changed simultaneously during the first clinic visit
- •Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator.
结局指标
主要结局
Medication dosing optimization
时间窗: 3 years
• Artificial intelligence guided treatment in chronic disease of hypertension and type 2 diabetes mellitus will yield actionable medication dosing optimization and to demonstrate technical development of artificial intelligence platform (CURATE.AI) using retrospective data in patients with hypertension and type 2 diabetes mellitus.
次要结局
- (CURATE.AI) pilot deployment using prospective data(3 years)
研究者
Amartya Mukhopadhyay
Senior Consultant, Division of Respiratory & Critical Care Medicine, Department of Medicine, National University Hospital
Alexandra Hospital